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In recent years methotrexate has been used increasingly in combination chemo-
therapeutic regimens for the treatment of aggressive non -Hodgkin's lymphoma. I
Itsprincipal toxic effects are bone marrow suppression, gastrointestinal mucositis,
hepatitis, renal impairment, and erythematous rashes. The Stevens-Johnson
syndrome has been reported previously in two children receiving high-dose
methotrexate with leucovorin rescue for treatment of acute lymphoblastic
leukaemia.2 Thesyndrome ischaracterized bysevere erythema multiformeassoc-
iated with orogenital mucosal ulceration, and may be complicated by severe
systemic upset and hepatic, renal and neurological disturbances.3 We report
a case of near-fatal Stevens-Johnson syndrome following intermediate dose
methotrexate and leucovorin rescue in a patient receiving combination chemo-
therapy for diffuse large cell non -Hodgkin's lymphoma.
CASEREPORT. A 54 -year-old man presented with cervical lymphadenopathy
and anabdominal mass. Cervical lymph node biopsy demonstrated adiffuse large
cell non-Hodgkin's lymphoma.4 Extensive involvement of mesenteric lymph
nodes wasdemonstrated by CTscanning. He wastreated with BCHOP -M chemo-
therapy intravenously: bleomycin 10mg, cyclophosphamide 1-4g, doxorubicin
76mg and vincristine 2mg on day 1; followed by oral prednisolone 40mg daily
on days 1-5 and intravenous methotrexate 380mg on day 15, and leucovorin
30mg orally six-hourly for four doses on day 16.
On days 22-24 he developed a fever, a generalised erythematous itchy rash,
and severe mucosal ulceration of the orpharynx, glans penis, and anus. He had
epidermal ulceration of the scrotum, perineum, and upper medial aspect of the
thighs. On days 25 -30 the rash became confluent over the whole body surface
and began toblister overthe trunk, palms and soles, gradually resolving over days
33-40.
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Figure. Neutrophil, eosinophil and platelet counts following methotrexate and leucovorin rescue.
The haemoglobin fell gradually from 15-4g/dl on day 1 to 9-2g/dl on day 21, rising to 9-6g/dl
on day 30. Blood transfusion was not required.
On day 18 he had been found to have pancytopenia associated with eosinophilia
(Figure). The bone marrow was hypocellular with gross megaloblastic changes
and no evidence of lymphomatous infiltration. He was given further doses of
leucovorin intravenously (30mg six-hourly for 48 hours) followed by oral folic
acid (15mg daily for 10 days), and hydroxocobalamin 1mg intravenously. The
peripheral blood countgraduallyimproved overdays20-24, buttheeosinophilia
persisted until day 29 and then gradually resolved. The period of pancytopenia
was complicated by bleeding from the ulcerated oropharyngeal mucosa and a
purpuric rash on the lower limbs. Staphylococcus aureus, Escherischia coli, and
Klebsiella pneumoniae were isolated from the skin, throat, sputum and blood. He
required support with platelet transfusions and intravenous antibiotics. During the
acute illness he had reversible renal and hepatocellular damage, but ultrasound
scan showed no evidence of ureteric or biliary obstruction.
By day 40 his temperature was normal and there was complete resolution of the
rash, complete healing of the orogenital ulceration, and normal liver, renal, and
bone marrow function. Subsequently he received five further pulses of BCHOP
without methotrexate, and had no recurrence ofthe Stevens-Johnson syndrome.
His non-Hodgkin's lymphoma remains in complete remission 36 months after
completion of chemotherapy.
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DISCUSSION
Although dermatological complications of methotrexate therapy appear to be
relatively rare, they may be serious when they do occur. Bullous skin reactions
have been reported in high-dose methotrexate regimens used in the treatment of
non -Hodgkin's lymphomas,5 and the Stevens-Johnson syndrome in two patients
treated for childhood acute lymphoblastic leukaemia.2
This case demonstrates that the Stevens-Johnson syndrome can occur following
intermediate dose methotrexate with leucovorin rescue in aggressive non-
Hodgkin's lymphoma. In any severe drug reaction in patients receiving multiple
agents, a cause-effect relationship can only be proven by selective re-challenge.
The reaction in our patient was temporarily related to methotrexate adminis-
tration, and did not recur when the patient received five further pulses of BCHOP
without methotrexate. The syndrome was not present before the initiation of
chemotherapy, suggesting that it was not part of the presenting features of his
lymphoma. He did have evidence of infection manifested by triple organism
septicaemia, but this occurred after the onset of the mucocutaneous reaction,
and was therefore more likely a complication than the cause. These arguments
provide strong support for a causal relationship between the Stevens-Johnson
syndrome and methotrexate administration in this case.
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